XDx’s AlloMap® Considered ‘Medically Necessary’ by Aetna Inc. for Heart Transplant Recipients - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Get our newsletter
Order Prints
March 8, 2011
Share
Share
Post
Email

XDx’s AlloMap® Considered ‘Medically Necessary’ by Aetna Inc. for Heart Transplant Recipients

AlloMapadded to Aetna’s clinical policy bulletin for heart transplantation

BRISBANE, Calif.--(BUSINESS WIRE)-- XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that Aetna Inc., one of the nation's leading providers of health care insurance, has determined that AlloMap® is “medically necessary” for monitoring rejection in heart transplant recipients more than one year after a heart transplant. With this determination, Aetna joins the growing list of insurers that recognize the clinical effectiveness of AlloMap molecular expression testing.

“We are pleased by Aetna’s decision and the resulting opportunity to expand our product and services offering to more patients,” said Pierre Cassigneul, president and CEO of XDx. “Recognition of AlloMap’s benefit for eligible heart transplant recipients by one of the leading providers of health care in the United States is an important validation of our tests and results. We hope to reduce the number of invasive biopsies that stable patients have to undergo post-transplant and thereby improve patients’ quality of life.”

Following heart transplants, patients typically undergo multiple endomyocardial biopsies, a highly invasive method of monitoring for post-transplant rejection. AlloMap is a simple, non-invasive blood test that can help physicians evaluate whether a patient is at low risk for heart transplant rejection. There are about 2,100 heart transplants in the United States each year and approximately 20,000 living recipients of heart transplants.

About AlloMap® Molecular Expression Technology

AlloMap Molecular Expression Testing is a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with a standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008.

About XDx

XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx’s non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit www.xdx.com.

Pure CommunicationsSheryl Seapy, 949-608-0841

Source: XDx, Inc.

Older

Scotiabank reports record earnings of $1,174 million for the first quarter

Newer

ACL Services to Present at Audit Leadership Conference

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
More Annuity News

Health/Employee Benefits News

  • EXPLORING INSULIN COST-SHARING CAPS FOR PATIENTS WITH PRIVATE COVERAGE
  • THE AMERICAN DIABETES ASSOCIATION FIGHTS TO MAINTAIN ACCESS TO HEALTH INSURANCE
  • Grand jury accuses veteran of making false disability claims that defrauded VA
  • States push short-term insurance as healthcare costs climb
  • Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
More Health/Employee Benefits News

Life Insurance News

  • FORMER PRINCE GEORGE'S COUNTY INSURANCE AGENT SENTENCED FOR FELONY INSURANCE THEFT SCHEME
  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.